January 19, 2021 -- Ion channel contract research organization Metrion Biosciences and U.K. medical research charity LifeArc have extended their neuroscience drug discovery collaboration for 12 months.
Under the terms of the deal, Metrion is providing its ion channel and electrophysiology-based assays and safety profiling services, while LifeArc is working to identify novel modulators of central nervous system ion-channel targets and all new chemical syntheses, according to the companies. Metrion is also utilizing both automated electrophysiology and manual patch clamp technologies to evaluate the pharmacological activities of LifeArc compounds.
An initial agreement between the firms was signed in January 2019 and then extended again in December 2019. After mutually agreed criteria were achieved, LifeArc said it has exercised its option to extend the collaboration for 12 more months.